Business Description
Paion Ag
ISIN : DE000A3E5EG5
Description
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.22 | |||||
| Equity-to-Asset | -0.1 | |||||
| Debt-to-Equity | -6.93 | |||||
| Debt-to-EBITDA | -1.44 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -6.37 | |||||
| Beneish M-Score | -0.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 56.9 | |||||
| 3-Year EPS without NRI Growth Rate | 57.8 | |||||
| 3-Year Book Growth Rate | -25.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.76 | |||||
| Quick Ratio | 0.51 | |||||
| Cash Ratio | 0.28 | |||||
| Days Inventory | 305.21 | |||||
| Days Sales Outstanding | 33.88 | |||||
| Days Payable | 586.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.9 | |||||
| Shareholder Yield % | -148.97 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.06 | |||||
| Operating Margin % | -118.22 | |||||
| Net Margin % | -134.12 | |||||
| FCF Margin % | -86.95 | |||||
| ROE % | -292.45 | |||||
| ROA % | -51.38 | |||||
| ROIC % | -69.32 | |||||
| ROC (Joel Greenblatt) % | -2170.06 | |||||
| ROCE % | -64.37 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 22.6 | |||||
| PS Ratio | 0.02 | |||||
| EV-to-EBIT | -1.02 | |||||
| EV-to-EBITDA | -1.14 | |||||
| EV-to-Revenue | 1.13 | |||||
| EV-to-FCF | -1.32 | |||||
| Earnings Yield (Greenblatt) % | -97.75 | |||||
| FCF Yield % | -5672.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Paion Ag Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 14.808 | ||
| EPS (TTM) (€) | -2.78 | ||
| Beta | -0.15 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 18.36 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 18.36 - 18.36 | ||
| Shares Outstanding (Mil) | 7.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Paion Ag Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Paion Ag Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Paion Ag Frequently Asked Questions
What is Paion Ag(LTS:0NF3)'s stock price today?
The current price of LTS:0NF3 is €18.36. The 52 week high of LTS:0NF3 is €18.36 and 52 week low is €18.36.
When is next earnings date of Paion Ag(LTS:0NF3)?
The next earnings date of Paion Ag(LTS:0NF3) is .
Does Paion Ag(LTS:0NF3) pay dividends? If so, how much?
Paion Ag(LTS:0NF3) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers